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Abstract
Background: The prevalence and clinical characteristics of neonatal candidemia are poorly understood in western
China. The aim of our study was to evaluate the epidemiological features of neonatal candidemia in the Liuzhou
Maternity and Child Healthcare Hospital.
Methods: A retrospective case-control study was conducted between January 2012 and November 2015. Electronic
databases were reviewed and data on Candida species were isolated from blood cultures and candidemia
incidence, risk factors, and mortality were extracted. Univariate and multivariate logistic regression analysis were
performed to identify risk factors associated with candidemia.
Results: During the 4-year period, candidemia was identified in 69 newborns, for an incidence rate of 13.6 per
1000 admissions. Prolonged antibiotic therapy duration [odds ratio (OR), 95% confidence incidence (95% CI) = 1.06,
1.01–1.10], total parenteral nutrition [OR, 95% CI = 6.03, 2.10–17.30] and neurodevelopmental impairment (OR, 95%
CI = 7.34, 1.18–45.80) were all associated with increased odds of candidemia development in infants (P value was 0.
010, 0.001, 0.033, respectively). The overall mortality rate was 7.2% in the candidemia group.
Conclusions: Prolonged duration of antibiotic therapy, presence of total parenteral nutrition and neurodevelopmental
impairment were the major risk factors associated with neonatal candidemia. This study highlights the importance of
the early detection, diagnosis and treatment of neonatal candidemia.
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Background
Candidiasis is one of the leading causes of bloodstream
infections in neonatal intensive care units (NICUs) and
associated with high morbidity and mortality. It has been
estimated that 2.4–9.0% of mortality [1, 2] and 25.0% of
morbidity [3] in the NICU setting may be attributable to
Candida infections.
Because of their immature specific and nonspecific im-
mune systems, neonates may be vulnerable to invasive
candidemia. Several factors have previously been identified
as contributing to an increased incidence of neonatal can-
didemia, including prolonged endotracheal intubation,
indwelling medical catheterization, parenteral nutrition,
use of broad-spectrum antibiotics, and prolonged anti-
biotic therapy duration. Because of the lack of specific
signs and symptoms and sensitive and specific laboratory
tests for the diagnosis of Candida infection, early diagno-
sis of candidemia remains crucial and is a challenge for
both pediatricians and microbiologists. Therefore, the
aims of the present study were to evaluate the incidence
and epidemiology of candidemia in infants and determine
the risk factors and clinical outcomes associated with can-
didemia to help pediatricians select effective preventive
measures and medical treatment for neonatal candidemia.
Methods
This retrospective study was conducted at the 60-bed
NICU of the Liuzhou Maternity and Child Healthcare
Hospital, which is the largest neonatal care center in
Liuzhou. Between 1000 and 1200 neonates are admitted
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to this NICU each year. Candidemia was defined by a
blood culture that yielded any Candida species. Micro-
biology laboratory and clinical records from two elec-
tronic databases were reviewed. The following data
were extracted: admission age, gender, gestational age,
birth weight, delivery mode, necrotizing enterocolitis,
neurodevelopmental impairment, maternal underlying
diseases, abdominal surgery, mechanical ventilation, in-
dwelling central venous catheterization, endotracheal
intubation, rescue history, total parenteral nutrition,
hospitalization duration, use of carbapenems, use of
vancomycin, multiple antibiotic (≥3 classes of antibi-
otics) use, antibiotic therapy duration and outcome of
candidemia. For each case, one neonate with negative
blood culture results was matched based on the follow-
ing factors to serve as a control: admission age, gender,
gestational age, and birth weight. These data were also
extracted as previously described.
Microbiologic methods
All microbiological testing was completed using standard
methodology. Candida were isolated from blood cultures
using the BacT/AlerT 3D rapid culture and monitoring
system (BioMérieux). Candida species were identified
using API 20C AuX (BioMérieux).
Statistical analysis
SPSS version 20.0 (SPSS Inc. Chicago, Il, USA) was used
for data analysis. Comparisons between the case and
control groups were performed using univariate analysis
methods. All variables with P < 0.05 were selected for
inclusion in the multivariate logistic regression model to
identify predisposing risk factors associated with neo-
natal candidemia.
Ethical considerations
Local ethics approval was obtained.
Results
Five thousand and seventy-five newborns were admitted
to the NICU from January 2012 to November 2015, and
69 newborns developed candidemia. In the case group,
the gestational age ranged from 27 weeks to 41 weeks and
birth weight ranged from 800 g to 3350 g. Of the 33
infants with extremely low birth weight (ELBW< 1000 g),
10 developed candidemia; of the 449 newborns were very
low birth weight (VLBW< 1500 g), 38 developed candide-
mia. The overall candidemia incidence was 13.6 per 1000
admissions. The highest candidemia incidence was ob-
served among ELBW infants (303.0 per 1000 ELBW in-
fants). The candidemia incidence among VLBW infants
was 84.6 per 1000 VLBW infants. The overall mortality
rate in the candidemia group was 7.2%, while the mortality
rate in the control group was 1.4%.
The most and almost equally prevalent pathogens iden-
tified were Candida albicans and Candida glabrata, with
30 (34.5) and 23 (33.3%) episodes of candidemia attributed
to Candida albicans and Candida glabrata, respectively.
The remaining episodes of candidemia were caused by
Candida tropicalis (14, 20.3%), Candida parapsilosis
(1, 1.4%) and Candida kefyr (1, 1.4%).
Patient demographics, clinical characteristics, and
prognosis were compared between the candidemia and
non-candidemia groups and are summarized in Table 1.
There were no significant differences in the following
variables between case and control patients: gestational
age, birth weight, admission age, gender and delivery
mode.
In the univariate logistic regression analyses, factors sig-
nificantly associated with candidemia were necrotizing
enterocolitis (P = 0.025), neurodevelopmental impair-
ment (P = 0.006), maternal underlying diseases (P =
0.035), mechanical ventilation (P = 0.011), central ven-
ous catheterization (P = 0.007), intubation (P = 0.013),
total parenteral nutrition (P = 0.000), prolonged
hospitalization duration (P = 0.000), carbapenem use
(P = 0.000), multiple antibiotic use (P = 0.000), antibiotic
therapy duration (P = 0.000), and the mortality due to can-
didemia (P = 0.043).
Forward step-wise multivariate logistic regression was
used to evaluate the risk factors for candidemia identi-
fied as significant in the univariate analyses, as shown
in Table 2. The results of this analysis showed that total
parenteral nutrition [odds ratio (OR) = 6.03, 95% confi-
dence interval (95% CI = 2.10–17.30, P = 0.001], anti-
biotic therapy duration (OR = 1.06, 95% CI = 1.01–1.10,
P = 0.010), and neurodevelopmental impairment (OR =
7.34, 95% CI = 1.18–45.80, P = 0.033) were significant
predictors of candidemia in the multivariate model.
Discussion
Candida species have emerged as a leading pathogenic
cause of bloodstream infections in neonates [1–3]. The
overall incidence of candidemia in our study was 13.6
per 1000 admissions. This incidence was lower than that
reported in a previous study conducted by Benjamin et
al. [1], in which a higher incidence (9%) was reported. In
the present study, we found that the overall incidence of
candidemia among VLBW infants was 84.6 per 1000 ad-
missions, and in the ELBW group, the candidemia inci-
dence was 303.0 per 1000 admissions. These findings are
consistent with the results of a study based on surveil-
lance data collected in England between 2004 and 2010,
which reported that ELBW infants had the highest risk
of invasive Candida infection of the neonates evaluated
[2]. During the 4-year period evaluated in our study,
only 33 ELBW infants survived and were admitted to
the NICU after delivery. One likely reason for the
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observed discrepancy is that the prevalence of VLBW,
especially ELBW, among infants is much higher in de-
veloped countries than in China [4]. These studies
highlighted the importance of infection control and early
identification of potential risk factors for the prevention
of candidemia among high risk infants.
In our study, the majority of candidemia episodes were
caused by C. albicans (43.5%) and C. glabrata (33.3%).
Previous studies, especially those conducted in western
countries, have frequently reported that C. albicans was
the most common causative agent of neonatal candidemia,
followed by C. parapsilosis [2]. In contrast with the results
of some previous studies, the results of our study paral-
leled those of a previous study conducted by Xia et al. [4],
who reported that C. albicans was the species most com-
monly identified in Chinese 11 NICU centers, followed by
C. glabrata. These results were consistent with the fact
that the predominant causative agents of candidemia may
vary by geographic region [5].
Previous studies have revealed that prophylactic or em-
piric therapy with antifungal agents, especially fluconazole,
may be associated with changes in Candida ecology and
antifungal agent susceptibility [6]. According to the micro-
biological data evaluated in our study, all of the tested
Candida isolates were susceptible to fluconazole, ampho-
tericin B and voriconazole. Fluconazole is considered as
the first line antifungal agent in our hospital. Previously, a
study showed that pre-exposure to fluconazole was a pre-
disposing factor for C. glabrata infection [7], which may
Table 1 Clinical characteristics of neonates with and without candidemia
Variable Case mean
(95% CI) or n(%)
Control mean
(95% CI) or n(%)
P value Odds ratio
(OR) (95% CI)
Demographics
Gestational age (wks) 31.7(28.2, 35.2) 31.6(27.8, 35.4) 0.763
Birth weight (g) 1514.4(852.0,2176.3) 1529.3(856.5,2202.1) 0.894
Male gender, n(%) 44(63.8) 41(59.4) 0.600 1.20(0.61–2.39)
Admission age 1.1(0.8, 1.4) 1.5(1.2, 4.2) 0.149
Risk factors
Vaginal delivery 28(40.6) 33(47.8) 0.392 0.75(0.38–1.46)
Necrotizing enterocolitis 16(23.2) 6(8.7) 0.025 3.17(1.16–8.68)
Neurodevelopmental impairment 14(20.3) 2(2.9) 0.006 8.52(1.86–39.14)
Maternal underlying diseases 31(44.9) 19(27.5) 0.035 2.15(1.06–4.37)
Abdominal surgery 10(14.5) 3(4.4) 0.057 3.67(0.96–13.99)
Mechanical ventilation 43(62.3) 28(40.6) 0.011 2.42(1.22–4.80)
Central venous catheter 40(58.0) 24(34.8) 0.007 2.59(1.30–5.15)
Intubation 31(44.9) 17(24.6) 0.013 2.50(1.21–5.15)
Rescue history 35(50.7) 26(37.7) 0.124 1.70(0.86–3.35)
Total parenteral nutrition 58(84.1) 23(33.3) 0.000 10.55(4.66–23.85)
Hospitalization duration (d) 46.6(23.3, 69.9) 24.5(5.7, 43.3) 0.000
3rd cephalosporins use 39(57.4) 29(42.0) 0.074 1.86(0.94–3.65)
Carbapenems use 50(72.5) 15(21.7) 0.000 9.47(4.35–20.64)
Vancomycin use 10(14.5) 5(7.2) 0.179 12.17(0.70–6.72)
Multiple antibiotic use 37(53.6) 9(13.0) 0.000 7.71(3.31–17.95)
Antibiotic therapeutic duration (d) 33.5(14.7, 52.3) 13.8(2.5, 25.1) 0.000
Outcome
Cure 16(23.2) 32(46.4) reference reference
Improvement 43(62.3) 33(47.8) 0.013 2.61(1.23–5.53)
Exacerbation 5(7.2) 3(4.3) 0.128 3.33(0.71–15.74)
Death 5(7.2) 1(1.4) 0.043 10.00(1.08–92.94)
Table 2 Multivariate analysis for candidemia
Risk factor Odds ratio 95% CI P value
Total parenteral nutrition 6.03 2.10–17.30 0.001
Antibiotic therapeutic duration (d) 1.06 1.01–1.10 0.010
Neurodevelopmental impairment 7.34 1.18–45.80 0.033
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partly explain the observed discrepancy regarding the dis-
tribution of Candida among neonates, as most NICUs
have been reported to use liposomal amphotericin B when
administering prophylactic or empiric therapy [2].
Central venous catheterization and total parenteral
nutrition were identified as significant predisposing fac-
tors for the development of candidemia in our study.
The majority of the infected neonates had received cen-
tral venous catheterization (58.0%), endotracheal intub-
ation (44.9%), and total parenteral nutrition (84.1%). The
multivariate logistic regression model results suggested
that total parenteral nutrition was the factor most highly
associated with increased odds of candidemia. Candida
species are notorious for their capacity to attach to for-
eign materials (such as invasive and indwelling devices)
and form biofilms, which may be associated with high
virulence and act as a biological barrier that prevents the
penetration of antifungal agents and protects the fungal
cells from the host’s immune responses. This fact may
explain why invasive and indwelling medical devices
have been identified as factors consistently associated
with increased risk of candidemia [5, 8].
Broad-spectrum antibiotic use has also been described
as a risk factor for candidemia [2, 9, 10]. In our depart-
ment, the majority of candidemia cases had received
broad-spectrum antibiotics, such as carbapenems (72.5),
and 53.6% of patients received multiple antibiotics. The
median antibiotic therapy duration was 33.5 days (range
14.7–52.3 days). A previous study conducted by Kaufman
et al. [11] showed that decreased use of carbapenem may
be associated with decreased incidence of invasive fungal
infections. It has been reported that prolonged exposure
to broad-spectrum antibiotics not only increases the risk
of developing neonatal candidemia [12] but also may be
associated with the development of refractory candidemia
[13]. The widespread use of antibacterial agents may
suppress bacterial flora and increase Candida colonization
density [14]. The results of our study were consistent with
those of a previous investigation conducted in 11 NICUs,
which revealed that broad-spectrum antibacterial agents
were commonly used for prophylactic or empiric therapy
in China [4]. This finding highlights the need to evaluate
the antimicrobial burden in local NICUs in China.
Our study revealed that neonatal candidemia was associ-
ated with neurodevelopmental impairment. Several studies
have also reported this conclusion. Two large prospective
cohort studies reported that systemic candidiasis was asso-
ciated with increased risk of death and/or neurodevelop-
mental impairment [15, 16] in extremely low birth weight
infants. Experimental data suggests that the cytokine-
mediated inflammatory responses mediated elicited by
infection may be neurotoxic and contribute to brain
damage. However, data regarding cytokine-mediated in-
flammatory responses to specific pathogens and their
relationship with adverse neurodevelopmental outcomes
are limited [17, 18]. It is of importance to evaluate poten-
tial mechanisms by which to reduce inflammatory re-
sponses and the risk of brain damage associated with
candidemia in future research.
As was identified in mainland China, the situation re-
lated to neonatal candidemia observed in this study was
also not optimistic. Studies have previously reported
incidence rates of candidemia ranging from 0.74 [4] to
15.7% [19] and mortality rates ranging from 8.9 [20] to
26.3% [21] in neonatal patients in mainland China. Our
results were consistent with those of previous investiga-
tions [4, 19, 22, 23] suggesting that very low birth weight
was an independent factor associated with the develop-
ment candidemia. Previous studies have identified C.
albicans as the predominant pathogen causing candidemia
in neonatal patients in China [4, 22]. Risk factors previ-
ously reported to be associated with neonatal candidemia
in China have included intubation [20], use of medical
catheters [20, 21, 23], use of high-level antibiotics [20, 21],
prior surgeries [20, 21], prolonged antibiotic use [21], and
preterm birth with low birth weight [4, 19, 22, 23].
The limitations of the current study were inherent
given its retrospective nature. The single center design
and small sample size may have compromised the statis-
tical power of the study. Furthermore, the diagnosis of
neurodevelopmental impairment was mostly based on
ophthalmological, otological, and radiological findings
and not systematically evaluated using the Gross Motor
Functional Classification Score and cognitive and motor
scales of the Bayley Scales of Infant Development-III
(BSID-III) [16]. Follow-up data regarding neuro- devel-
opmental impairment in the infants included in this
study were not available. Further studies should focus on
this aspect of candidemia risk. Nevertheless, these data
provide information regarding the epidemiology of neo-
natal candidemia in western China. It is crucial for local
pediatricians to promote the prevention, early detection
and treatment of candidemia in high risk neonates.
Conclusions
In conclusion, our findings suggest that prolonged antibiotic
therapy duration, presence of total parenteral nutrition and
neurodevelopmental impairment were associated with in-
creased odds of neonatal candidemia. The identification of
risk factors associated with increased odds of neonatal
candidemia emphasizes the need for early detection, diag-
nosis and treatment of Candidiasis infections in NICUs.
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